Lycia Therapeutics
South San Francisco, US · Founded 2019 · Delaware corporation · 36 employees on LinkedIn · 12 known investors
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.
Founders & leadership
AW
Aetna Wun TrombleyPresident and CEO
AB
Amy BachrodtChief Financial Officer
JS
CL
Chin LeeChief Medical Officer
SS
Steve StabenChief Scientific Officer
ST
Sofia TouamiChief Business Officer
KF
Karen FlickGeneral Counsel
Board
CO
TW
TA
Tim AndersonBoard director
WR
William RieflinBoard director
LF
Laurent FischerBoard director
Investors · 12
REDMILE✓ verifiedSan Francisco
Versant Ventures✓ verifiedSan Francisco · $250K – $5Mvia Clare Ozawa · board
BAM Elevatereported · 2 sourcesChicago
Franklin Templetonreported · 2 sourcesSan Mateo
HBM Healthcare Investmentsreported · 2 sourcesZug
InvusreportedNew York
Janus Henderson Investorsreported · 2 sourcesLondon
OrbiMedreported · 2 sourcesNew York · $1M – $75M
RTW Investments L.P.reported · 2 sourcesNew York
Venrock Healthcare Capital Partnersreported · 2 sourcesNew York
Versant Venture CapitalreportedSan Francisco
Also in the syndicate · 1
Eli Lilly and Company
Reported raises · per SEC filings
Form D private placements$277M disclosed across 4 rounds · 2020–2026
▶$75MraisedJun 2026 · 16 investors · BiotechnologyRule 506(b)
▶$75MraisedJun 2026 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tim AndersonDirector
- William RieflinDirector
- Clare OzawaDirector
- Aetna Wun TrombleyExecutive Officer, Director
- Laurent FischerDirector
- Ming FangDirector
- Amy BachrodtExecutive Officer
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$106.6MraisedMay 2024 · 16 investors · BiotechnologyRule 506(b)
▶$106.6MraisedMay 2024 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ming FangDirector
- Laurent FischerDirector
- Tim AndersonDirector
- Andrew GottesdienerDirector
- William RieflinDirector
- Clare OzawaDirector
- Aetna Wun TrombleyExecutive Officer, Director
- Offering amount
- $106.6M
- Amount sold
- $106.6M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$70.1MraisedSep 2021 · 11 investors · BiotechnologyRule 506(b)
▶$70.1MraisedSep 2021 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laurent FischerDirector
- William RieflinDirector
- Clare OzawaDirector
- Thomas WoiwodeDirector
- Tim AndersonDirector
- Aetna Wun TrombleyExecutive Officer, Director
- Offering amount
- $70.1M
- Amount sold
- $70.1M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$25.4MraisedMar 2020 · 1 investors · BiotechnologyRule 506(b)
▶$25.4MraisedMar 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Clare OzawaDirector
- Thomas WoiwodeDirector
- Laurent FischerDirector
- Jeremy S. CaldwellExecutive Officer, Director
- Offering amount
- $50.4M
- Amount sold
- $25.4M
- Minimum investment
- $1
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Intellia Therapeutics18 shared keywordsIntellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis. The company operates as a clinical-stage biopharmaceutical company pursuing potentially curative treatments from discovery through commercialization.
Kite Pharma17 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Coya Therapeutics16 shared keywords
Altay Therapeutics15 shared keywordsAltay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
Companies competing with Lycia Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Lycia Therapeutics has filed a notice of an exempt offering of securities to raise $75 Million in New Funding. - intelligence360intelligence360.news · Jul 2026
Lycia Raises $75M for Protein Degradation Trialsallsci.com · Jun 2026Frequently asked questions
- What does Lycia Therapeutics do?
- Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation. Its targeted protein degradation platform, based on research from Carolyn Bertozzi's lab at Stanford, aims to address proteins previously considered undruggable.
- Who are Lycia Therapeutics's investors?
- Lycia Therapeutics's investors include REDMILE, Versant Ventures, BAM Elevate, Franklin Templeton, HBM Healthcare Investments, Invus, Janus Henderson Investors, OrbiMed and 3 more.
- How much funding has Lycia Therapeutics raised?
- Lycia Therapeutics has disclosed $277M raised across 4 rounds.
- Where is Lycia Therapeutics headquartered?
- Lycia Therapeutics is headquartered in South San Francisco, US.